Barbara Pavan

List of Publications by Year
in descending order

72 papers	1,856 citations	218381 26 h-index	301761 39 g-index
72 all docs	72 docs citations	72 times ranked	2552 citing authors

#	Article	IF	Citations
1	Progress in Drug Delivery to the Central Nervous System by the Prodrug Approach. Molecules, 2008, 13, 1035-1065.	1.7	124
2	Design, Synthesis and Activity of Ascorbic Acid Prodrugs of Nipecotic, Kynurenic and Diclophenamic Acids, Liable to Increase Neurotropic Activity. Journal of Medicinal Chemistry, 2002, 45, 559-562.	2.9	99
3	Brain targeting of resveratrol by nasal administration of chitosan-coated lipid microparticles. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 127, 250-259.	2.0	64
4	Zidovudine and Ursodeoxycholic Acid Conjugation: Design of a New Prodrug Potentially Able To Bypass the Active Efflux Transport Systems of the Central Nervous System. Molecular Pharmaceutics, 2012, 9, 957-968.	2.3	60
5	Geraniol Pharmacokinetics, Bioavailability and Its Multiple Effects on the Liver Antioxidant and Xenobiotic-Metabolizing Enzymes. Frontiers in Pharmacology, 2018, 9, 18.	1.6	60
6	Nasal administration of nanoencapsulated geraniol/ursodeoxycholic acid conjugate: Towards a new approach for the management of Parkinson's disease. Journal of Controlled Release, 2020, 321, 540-552.	4.8	57
7	Nasal chitosan microparticles target a zidovudine prodrug to brain HIV sanctuaries. Antiviral Research, 2015, 123, 146-157.	1.9	56
8	Adenylyl cyclases as innovative therapeutic goals. Drug Discovery Today, 2009, 14, 982-991.	3.2	55
9	Responses of peripheral blood mononucleated cells from non-celiac gluten sensitive patients to various cereal sources. Food Chemistry, 2015, 176, 167-174.	4.2	51
10	Indomethacin Co-Crystals and Their Parent Mixtures: Does the Intestinal Barrier Recognize Them Differently?. Molecular Pharmaceutics, 2015, 12, 1501-1511.	2.3	51
11	Brain Uptake of a Zidovudine Prodrug after Nasal Administration of Solid Lipid Microparticles. Molecular Pharmaceutics, 2014, 11, 1550-1561.	2.3	47
12	Can pharmaceutical co-crystals provide an opportunity to modify the biological properties of drugs?. Drug Discovery Today, 2017, 22, 1134-1138.	3.2	47
13	Beta-Adrenoreceptor Agonism Influences Retinal Responses to Hypoxia in a Model of Retinopathy of Prematurity. , 2012, 53, 2181.		42
14	The Role and Modulation of the Oxidative Balance in Pregnancy. Current Pharmaceutical Design, 2005, 11, 2075-2089.	0.9	40
15	Processing of adenosine receptor agonists in rat and human whole blood. Biochemical Pharmacology, 1998, 56, 1625-1632.	2.0	38
16	Compensatory changes in the hippocampus of somatostatin knockout mice: upregulation of somatostatin receptor 2 and its function in the control of bursting activity and synaptic transmission. European Journal of Neuroscience, 2006, 23, 2404-2422.	1.2	37
17	Design, synthesis and in vitro evaluation on HRPE cells of ascorbic and 6-bromoascorbic acid conjugates with neuroactive molecules. Bioorganic and Medicinal Chemistry, 2004, 12, 5453-5463.	1.4	34
18	From Physical Mixtures to Co-Crystals: How the Coformers Can Modify Solubility and Biological Activity of Carbamazepine. Molecular Pharmaceutics, 2018, 15, 268-278.	2.3	34

#	Article	IF	Citations
19	Somatostatin (SRIF) modulates distinct signaling pathways in rat pituitary tumor cells; negative coupling of SRIF receptor subtypes 1 and 2 to arachidonic acid release. Naunyn-Schmiedeberg's Archives of Pharmacology, 2002, 365, 200-209.	1.4	33
20	Somatostatin coupling to adenylyl cyclase activity in the mouse retina. Naunyn-Schmiedeberg's Archives of Pharmacology, 2004, 370, 91-98.	1.4	33
21	Ascorbic and 6-Br-ascorbic acid conjugates as a tool to increase the therapeutic effects of potentially central active drugs. European Journal of Pharmaceutical Sciences, 2005, 24, 259-269.	1.9	33
22	Prodrugs and Endogenous Transporters: Are They Suitable Tools for Drug Targeting into the Central Nervous System?. Current Pharmaceutical Design, 2011, 17, 3560-3576.	0.9	33
23	The Role of Combined Penetration Enhancers in Nasal Microspheres on In Vivo Drug Bioavailability. Pharmaceutics, 2018, 10, 206.	2.0	31
24	Modulation of neutrophil phospholipase C activity and cyclic AMP levels by fMLP-OMe analogues. Cellular Signalling, 2001, 13, 233-240.	1.7	30
25	A Novel Conjugated Agent between Dopamine and an A_{2A} Adenosine Receptor Antagonist as a Potential Anti-Parkinson Multitarget Approach. Molecular Pharmaceutics, 2012, 9, 591-604.	2.3	29
26	High glucose-induced barrier impairment of human retinal pigment epithelium is ameliorated by treatment with Goji berry extracts through modulation of cAMP levels. Experimental Eye Research, 2014, 120, 50-54.	1.2	28
27	Multidrug resistance in cancer or inefficacy of neuroactive agents: innovative strategies to inhibit or circumvent the active efflux transporters selectively. Drug Discovery Today, 2014, 19, 1563-1571.	3.2	27
28	Synthesis and study of 5'-ester prodrugs of N6-cyclopentyladenosine, a selective A1 receptor agonist. Pharmaceutical Research, 2001, 18, 531-536.	1.7	26
29	Nose-to-Brain Delivery of Antiviral Drugs: A Way to Overcome Their Active Efflux?. Pharmaceutics, 2018, 10, 39.	2.0	26
30	Retinal pigment epithelial cells as a therapeutic tool and target against retinopathies. Drug Discovery Today, 2018, 23, 1672-1679.	3.2	25
31	Application of the â€œin-oil nanoprecipitationâ€•method in the encapsulation of hydrophilic drugs in PLGA nanoparticles. Journal of Drug Delivery Science and Technology, 2016, 32, 283-290.	1.4	24
32	Circadian clocks regulate adenylyl cyclase activity rhythms in human RPE cells. Biochemical and Biophysical Research Communications, 2006, 350, 169-173.	1.0	23
33	Influence of oxytocin on prostaglandin E2, intracellular calcium, and cyclic adenosine monophosphate in human amnionâ€“derived (WISH) cells. American Journal of Obstetrics and Gynecology, 2000, 183, 76-82.	0.7	22
34	Development and characterization of biodegradable nanospheres as delivery systems of anti-ischemic adenosine derivatives. Biomaterials, 2005, 26, 1299-1306.	5.7	22
35	Bile salt-coating modulates the macrophage uptake of nanocores constituted by a zidovudine prodrug and enhances its nose-to-brain delivery. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 144, 91-100.	2.0	22
36	Transporter-Mediated Effects of Diclofenamic Acid and its Ascorbyl Pro-Drug in the in Vivo Neurotropic Activity of Ascorbyl Nipecotic Acid Conjugate. Journal of Pharmaceutical Sciences, 2004, 93, 78-85.	1.6	21

#	Article	IF	Citations
37	Inhibition of Amniotic Interleukin-6 and Prostaglandin E2 Release by Ampicillin. Obstetrics and Gynecology, 2004, 103, 108-113.	1.2	20
38	Cancer stem cells and nanomedicine: new opportunities to combat multidrug resistance?. Drug Discovery Today, 2020, 25, 1651-1667.	3.2	20
39	Inhibition of amniotic prostaglandin E release by ampicillin. American Journal of Obstetrics and Gynecology, 1998, 178, 759-764.	0.7	17
40	Development and characterization of PLGA nanoparticles as delivery systems of a prodrug of zidovudine obtained by its conjugation with ursodeoxycholic acid. Drug Delivery, 2014, 21, 221-232.	2.5	17
41	Nuclear Retinoic Acid Receptor Beta as a Tool in Chemoprevention Trials. Current Medicinal Chemistry, 2006, 13, 3553-3563.	1.2	16
42	Fabrication via a nonaqueous nanoprecipitation method, characterization and in vitro biological behavior of N6-cyclopentyladenosine-loaded nanoparticles. Journal of Pharmaceutical Sciences, 2009, 98, 4272-4284.	1.6	16
43	17Î²-Estradiol Stimulates Arachidonate Release from Human Amnion-Like WISH Cells through a Rapid Mechanism Involving a Membrane Receptor. Endocrinology, 2003, 144, 3359-3367.	1.4	15
44	Poly(lactic acid) microspheres for the sustained release of a selective A1 receptor agonist. Journal of Controlled Release, 2001, 73, 303-313.	4.8	14
45	Involvement of the cAMP-dependent pathway in the reduction of epileptiform bursting caused by somatostatin in the mouse hippocampus. Naunyn-Schmiedeberg's Archives of Pharmacology, 2008, 378, 563-577.	1.4	13
46	Uptake in the Central Nervous System of Geraniol Oil Encapsulated in Chitosan Oleate Following Nasal and Oral Administration. Pharmaceutics, 2019, 11, 106.	2.0	13
47	Versatile Nasal Application of Cyclodextrins: Excipients and/or Actives?. Pharmaceutics, 2021, 13, 1180.	2.0	13
48	Targeting Systems to the Brain Obtained by Merging Prodrugs, Nanoparticles, and Nasal Administration. Pharmaceutics, 2021, 13, 1144.	2.0	13
49	Adenylyl Cyclase/cAMP System Involvement in the Antiangiogenic Effect of Somatostatin in the Retina. Results from Transgenic Mice. Neurochemical Research, 2008, 33, 1247-1255.	1.6	12
50	Effect of different classes of antibiotics on amniotic prostaglandin e release. Prostaglandins and Other Lipid Mediators, 1999, 57, 207-218.	1.0	11
51	Interactions between the nitric oxide and prostaglandin E2 biosynthetic pathways in human amnion-like WISH cells. Journal of Reproductive Immunology, 2003, 60, 35-52.	0.8	11
52	Odorants could elicit repair processes in melanized neuronal and skin cells. Neural Regeneration Research, 2017, 12, 1401.	1.6	11
53	17Î²-Estradiol Modulates Prostaglandin E2 Release from Human Amnion-Derived WISH Cells1. Biology of Reproduction, 2001, 64, 1677-1681.	1.2	10
54	Evaluation of the In Vitro Biocompatibility of PEDOT:Nafion Coatings. Nanomaterials, 2021, 11, 2022.	1.9	10

#	Article	IF	Citations
55	Cocrystals of Nitrofurantoin: How Coformers Can Modify Its Solubility and Permeability Across Intestinal Cell Monolayers. Crystal Growth and Design, 2022, 22, 3090-3106.	1.4	10
56	The cyclooxygenase-2/prostaglandin E2 pathway is involved in the somatostatin-induced decrease of epileptiform bursting in the mouse hippocampus. Neuropharmacology, 2008, 54, 874-884.	2.0	9
57	Chitosan/heparin polyelectrolyte complexes as ion-paring approach to encapsulate heparin in orally administrable SLN: In vitro evaluation. Colloids and Surfaces A: Physicochemical and Engineering Aspects, 2021, 608, 125606.	2.3	9
58	Adenosine analogs inhibit acetylcholine release and cyclic AMP synthesis in the guinea-pig superior cervical ganglion. Neuroscience Letters, 1995, 184, 97-100.	1.0	8
59	Formyl-Methionyl-Leucyl-Phenylalanine Induces Prostaglandin E2 Release from Human Amnion-Derived WISH Cells by Phospholipase C-Mediated [Ca2+]i Rise1. Biology of Reproduction, 2001, 64, 865-870.	1.2	8
60	Biological activity of for-Met-Leu-Phe-OMe analogs: Relevant substitutions specifically trigger killing mechanisms in human neutrophils. European Journal of Pharmacology, 2005, 512, 1-8.	1.7	8
61	A novel hybrid drug between two potent anti-tubulin agents as a potential prolonged anticancer approach. European Journal of Pharmaceutical Sciences, 2016, 91, 50-63.	1.9	8
62	Polymeric nanomicelles based on inulin D Î±-tocopherol succinate for the treatment of diabetic retinopathy. Journal of Drug Delivery Science and Technology, 2021, 61, 102286.	1.4	8
63	Quercetin and quercetin-3-O-glucoside interact with different components of the cAMP signaling cascade in human retinal pigment epithelial cells. Life Sciences, 2015, 121, 166-173.	2.0	7
64	Potential therapeutic effects of odorants through their ectopic receptors in pigmented cells. Drug Discovery Today, 2017, 22, 1123-1130.	3.2	7
65	Thermodynamic in vitro studies as a method to investigate the pharmacodynamic behavior of adenosine A1 receptor ligands. Pharmaceutical Research, 1999, 16, 1054-1058.	1.7	6
66	Temperature dependence of the affinity enhancement of selective adenosine A1 receptor agonism: a thermodynamic analysis. European Journal of Pharmacology, 2002, 448, 123-131.	1.7	6
67	An RPE cell line as a useful in vitro model for studying retinoic acid receptor Î²: expression and affinity. Bioscience Reports, 2008, 28, 327-334.	1.1	6
68	Estrogen metabolites in the release of inflammatory mediators from human amnion-derived cells. Life Sciences, 2011, 88, 551-558.	2.0	6
69	â€œLowâ€•concentrations of sodium fluoride inhibit neurotransmitter release from the guinea-pig superior cervical ganglion. Neuroscience Letters, 2004, 364, 86-89.	1.0	5
70	Dopamine-sensitive adenylyl cyclases in neuronal development: physiopathological and pharmacological implications. Drug Discovery Today, 2011, 16, 520-529.	3.2	5
71	Evidence for the presence of N-formyl-methionyl-leucyl-phenylalanine (fMLP) receptor ligands in human amniotic fluid and fMLP receptor modulation by physiological labour. Journal of Reproductive Immunology, 2005, 68, 71-83.	0.8	3
72	Drug Release from Pharmaceutical Co-Crystals: Are Therapeutic and Safety Properties of Active Pharmaceutical Substances Retained?. Current Drug Delivery, 2019, 16, 486-489.	0.8	1